The long-running case sees an initial conclusion made, after a settlement agreement is put in place between JHL Biotech and Genentech over claims that the former company benefitted from stolen proprietary information in the development of its biosimilar pipeline. As a result of the agreement, the Taiwanese biotech agreed to stop clinical trials and the manufacture of biosimilars related to the case.
After it was discovered that rubber particles were detaching into the cartridges of Natpara (parathyroid hormone) products, Takeda initiated a recall of all lots from the US market. The situation was of particular concern due to the fact that Natpara is the only available adjunctive treatment for adult patients with chronic hypoparathyroidism.
Chinese company, CC-Pharming, agreed an exclusive licensing deal with iBio to commercialize a rituximab biosimilar to the Chinese market. A novel element of the agreement sees CC-Pharming utilize iBio’s plant-based manufacturing method to produce the biosimilars in China.
It was announced that GE Healthcare and Germfree would collaborate to make available a ready-made manufacturing solution, which could be used to develop gene therapies. The solution is scalable all the way through to commercialization, which the companies stated could aid the current issue with capacity in the area.
Merck, known as MSD outside of North America and Mexico, revealed its production plans for its investigational Ebola vaccine, after it received priority review designation from the US Food and Drug Administration. Over the next 6-to-18 months, the company will produce 650,000 doses of the vaccine, as the investigational drug continues to be used in the Democratic Republic of Congo to control outbreaks of the virus in the country.